1978 1980 1981 1982 1983 1984

1985 1986 1987 1988 1989 1990

1992 1993 1994 1995 1996 1997

1998 1999 2000 2001 2002 2003

2004 2005 2006 2007 2008

Demonstrability of the glycoprotein A-80 in postradiation prostatic carcinoma.
Magi-Galluzzi C, Nagy S, Bostwick DG, Cheng L, Gould VE.

ASAP is a valid diagnosis. Atypical small acinar proliferation.
Iczkowski KA, Cheng L, Qian J, Shanks J, Gadaleanu V, Bostwick DG, Ramnani DM.

Overexpression of the EphA2 tyrosine kinase in prostate cancer.
Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, Kinch MS.

Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications.
Cheng L, Neumann RM, Bostwick DG.

Urothelial papilloma of the bladder. Clinical and biologic implications.
Cheng L, Darson M, Cheville JC, Neumann RM, Zincke H, Nehra A, Bostwick DG.

Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder.
Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT.

Correlation of margin status and extraprostatic extension with progression of prostate carcinoma.
Cheng L, Darson MF, Bergstralh EJ, Slezak J, Myers RP, Bostwick DG.

Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer.
Bostwick DG, Foster CS.

Prostate-specific antigen and other serum markers: current concepts from the World Health Organization Second International Consultation on Prostate Cancer.
Brawer MK, Benson MC, Bostwick DG, Djavan B, Lilja H, Semjonow A, Su S, Zhou Z.

Overdiagnosis of prostatic adenocarcinoma.
Bostwick DG, Chang L.

Prostatic intraepithelial neoplasia is a risk factor for cancer.
Bostwick DG.

Prostate biopsy 1999: strategies and significance of pathological findings.
Iczkowski KA, Bostwick DG.

Diagnosis of prostate cancer in needle biopsies after radiation therapy.
Cheng L, Cheville JC, Bostwick DG.

Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.
Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AL, Scherer BG, Blute ML, Zincke H, Bostwick DG.

Predicting cancer progression in patients with stage T1 bladder carcinoma.
Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG.

Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, Grizzle WE.

Progression of T1 bladder tumors: better staging or better biology?: reply
Cheng L, Bostwick DG.

Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: A new proposal.
Cheng L, Weaver AL, Neumann RM, Scherer BG, Bostwick DG.

Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.
Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, Jenkins RB.

What is the significance of race to prostate carcinoma?
Bostwick DG.

Loss of heterozygosity on chromosome 13 is associated with advanced stage prostate cancer.
Afonso A, Emmert-Buck MR, Duray PH, Bostwick DG, Linehan WM, Vocke CD.

Transforming growth factor-beta1 (TGF-beta1) is sufficient to induce fibrosis of rabbit corpus cavernosum in vivo.
Nehra A, Gettman MT, Nugent M, Bostwick DG, Barrett DM, Goldstein I, Krane RJ, Moreland RB.

Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, Bostwick DG.

Dedifferentiation in the metastatic progression of prostate carcinoma.
Cheng L, Slezak J, Bergstralh EJ, Cheville JC, Sweat S, Zincke H, Bostwick DG.

Neurofibroma of the urinary bladder.
Cheng L, Scheithauer BW, Leibovich BC, Ramnani DM, Cheville JC, Bostwick DG.

Hemangioma of the urinary bladder.
Cheng L, Nascimento AG, Neumann RM, Nehra A, Cheville JC, Ramnani DM, Leibovich BC, Bostwick DG.

Small cell carcinoma of urinary bladder is differentiated from urothelial carcinoma by chromogranin expression, absence of CD44 variant 6 expression, a unique pattern of cytokeratin expression, and more intense gamma-enolase expression.
Iczkowski KA, Shanks JH, Allsbrook WC, Lopez-Beltran A, Pantazis CG, Collins TR, Wetherington RW, Bostwick DG.

Chromosome 16 allelic loss analysis of a large set of microdissected prostate carcinomas.
Strup SE, Pozzatti RO, Florence CD, Emmert-Buck MR, Duray PH, Liotta LA, Bostwick DG, Linehan WM, Vocke CD.

Diagnosis and classification of renal cell carcinoma.
Bostwick DG, Eble JN.

Diagnosis and grading of bladder cancer and associated lesions.
Bostwick DG, Ramnani D, Cheng L.

Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy.
Bostwick DG, Ramnani D, Cheng L.

Prostate biopsy interpretation. Current concepts, 1999.
Iczkowski KA, Bostwick DG.

Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy.
Cheng L, Cheville JC, Pisansky TM, Sebo TJ, Slezak J, Bergstralh EJ, Neumann RM, Singh R, Pacelli A, Zincke H, Bostwick DG.

Does prostatic ductal adenocarcinoma exist?
Bock BJ, Bostwick DG.

Villous adenoma of the urinary tract: a report of 23 cases, including 8 with coexistent adenocarcinoma.
Cheng L, Montironi R, Bostwick DG.

Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma.
Dechet CB, Bostwick DG, Blute ML, Bryant SC, Zincke H.

Does transurethral microwave thermotherapy have a different effect on prostate cancer than on benign or hyperplastic tissue?
Khair AA, Pacelli A, Iczkowski KA, Cheng L, Corica FA, Larson TR, Corica A, Bostwick DG.

Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion.
Cheng L, Neumann RM, Scherer BG, Weaver AL, Leibovich BC, Nehra A, Zincke H, Bostwick DG.

The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy.
Davis BJ, Pisansky TM, Wilson TM, Rothenberg HJ, Pacelli A, Hillman DW, Sargent DJ, Bostwick DG.

Survival of patients with carcinoma in situ of the urinary bladder.
Cheng L, Cheville JC, Neumann RM, Leibovich BC, Egan KS, Spotts BE, Bostwick DG.

p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression?
Cheng L, Leibovich BC, Bergstralh EJ, Scherer BG, Pacelli A, Ramnani DM, Zincke H, Bostwick DG.

Allelic imbalance in the clonal evolution of prostate carcinoma.
Cheng L, Bostwick DG, Li G, Wang Q, Hu N, Vortmeyer AO, Zhuang Z.

Basal cell-specific anti-keratin antibody 34betaE12: optimizing its use in distinguishing benign prostate and cancer.
Ramnani DM, Bostwick DG.

Mutation and expression analysis of the p73 gene in prostate cancer.
Yokomizo A, Mai M, Bostwick DG, Tindall DJ, Qian J, Cheng L, Jenkins RB, Smith DI, Liu W.

Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Saeid MS, Young CY, Klee GG, Tindall DJ, Bostwick DG.

Natural history of urothelial dysplasia of the bladder.
Cheng L, Cheville JC, Neumann RM, Bostwick DG.

Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Cheng L, Bostwick DG.

Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Bostwick DG.

Predictors of cancer progression in T1a prostate adenocarcinoma.
Cheng L, Bergstralh EJ, Scherer BG, Neumann RM, Blute ML, Zincke H, Bostwick DG.

p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L, Sebo TJ, Cheville JC, Pisansky TM, Slezak J, Bergstralh EJ, Pacelli A, Neumann RM, Zincke H, Bostwick DG.

Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.
Corica FA, Jacobsen SJ, King BF, Bostwick DG, Jacobson DJ, Girman CJ, Lieber MM.

Clinically unsuspected and undetected (clinical stage t0) prostate cancer diagnosed on random needle biopsy.
Corica FA, Bostwick DG.

Overexpression of the wild type p73 gene in human bladder cancer.
Yokomizo A, Mai M, Tindall DJ, Cheng L, Bostwick DG, Naito S, Smith DI, Liu W.

Sarcomas and related proliferative lesions of specialized prostatic stroma.
Colby TV, Bostwick DG.

Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long-term followup.
Corica FA, Iczkowski KA, Cheng L, Zincke H, Blute ML, Wendel A, Sebo TJ, Neumann R, Bostwick DG.

Subepithelial pelvic hematoma of the kidney clinically mimicking cancer: report of six cases and review of the literature.
Iczkowski KA, Sweat SD, Bostwick DG.

Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans.
Mohan RR, Challa A, Gupta S, Bostwick DG, Ahmad N, Agarwal R, Marengo SR, Amini SB, Paras F, MacLennan GT, Resnick MI, Mukhtar H.

Reversibility of prostatic intraepithelial neoplasia: implications for chemoprevention.
Bostwick DG, Neumann R, Qian J, Cheng L.

Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization.
Qian J, Jenkins RB, Bostwick DG.

Steam heat with an EDTA buffer and protease digestion optimizes immunohistochemical expression of basal cell-specific antikeratin 34betaE12 to discriminate cancer in prostatic epithelium.
Iczkowski KA, Cheng L, Crawford BG, Bostwick DG.

Pathologic Handling and Reporting of Prostate Tissue Specimens in Patients Receiving Neoadjuvant Hormonal Therapy: Report of the Pathology Committee.
Grignon DJ, Bostwick DG, Civantos F, Garnick MB, Gaudin P, Srigley JR.